Pharnext SA a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomic data and artificial intelligence, announced the issuance of composition of matter patent, securing protection as new entities, for PLEODRUG™ product, PXT3003.
“These issued patents confirm the recognition by the patent offices of Pharnext’s innovative drug combinations – or PLEODRUG™ – as new products,” said Prof. Daniel Cohen, M.D., Ph.D., Pharnext’s CoFounder and Chief Executive Officer.
“The patents contribute to the strength of Pharnext’s long-term intellectual property portfolio coverage for PXT3003 and PXT864, which are already well advanced in development.” The Canadian Intellectual Property Office (CIPO) issued a composition of matter patent (No. CA2763495) for PXT3003, which expires in 2030. This patent provides protection for PXT3003 per se, not limited to any therapeutic application, and protects its use in the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A).
See the Partnext´s patent portfolio – Click here-> Pharnext Patent Families
Just go back on viagra uk online what kind of attractive life you were living in your young time. But women who lack their desire for sex or viagra prices online not available for that moment may do hand practice. Merck’s five-year clinical tracking of 279 men on Propecia revealed the following: 42 percent visibly halted hair loss (according to blind assessments of photos by dermatologists) 48 percent visibly regrew hair (according to blind assessments of photos by dermatologists) 48 percent visibly regrew hair (according to blind assessments of photos by dermatologists) 66 percent regrew hair, as measured by hair counts cheap cialis soft As with minoxidil, use of Propecia needs. As a favor idea you could buy bath salts and fun containers so guests could create their own bath salt favor.This isn’t something to http://appalachianmagazine.com/2017/02/20/breaking-wvu-basketball-coach-bob-huggins-has-health-scare-during-game-blames-defibrillator/ viagra samples sweat about.
The issuance of these Canadian and European patents further contributes to Pharnext’s robust intellectual property portfolio covering PXT3003 and PXT864. Similar composition of matter patents have been granted in the U.S., Europe and Japan for PXT3003, and in the U.S. and Japan for PXT864.
These patents further confirm Pharnext’s innovative drug developments are covered by the same level of robust protection as traditional new chemical entities. In total, Pharnext’s research and development platform has produced a patent portfolio comprising over 540 issued patents covering key pharmaceutical markets.
Region France, Canada
Company Name Pharnext